Randomized, Double-Blind and Active-Controlled Study in Children and Adolescents Aged 317 Years to Assess the Safety and Immunogenicity of Abbott's Candidate Quadrivalent Influenza Vaccine and its Non-Inferiority versus Trivalent Influenza Vaccine.

Trial Profile

Randomized, Double-Blind and Active-Controlled Study in Children and Adolescents Aged 317 Years to Assess the Safety and Immunogenicity of Abbott's Candidate Quadrivalent Influenza Vaccine and its Non-Inferiority versus Trivalent Influenza Vaccine.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Influenza vaccine quadrivalent Abbott Biologicals (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors Abbott Biologicals BV
  • Most Recent Events

    • 15 Sep 2017 Status changed from recruiting to completed.
    • 31 Jul 2017 This trial has been completed in Finland (on-2017-04-14) according to European Clinical Trials Database record.
    • 06 Jul 2017 Trial has been completed inLithuania (end Date: 2017-04-14).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top